DOCSLIB.ORG

82 Part 1308—Schedules of Controlled Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
82 Part 1308—Schedules of Controlled Substances § 1307.22 21 CFR Ch. II (4±1±96 Edition) laws and regulations adopted by any SCHEDULES State. 1308.11 Schedule I. [36 FR 7801, Apr. 24, 1971, as amended at 37 1308.12 Schedule II. FR 15922, Aug. 8, 1972. Redesignated at 38 FR 1308.13 Schedule III. 26609, Sept. 24, 1973, and amended at 47 FR 1308.14 Schedule IV. 41735, Sept. 22, 1982] 1308.15 Schedule V. § 1307.22 Disposal of controlled sub- EXCLUDED NONNARCOTIC SUBSTANCES stances by the Administration. 1308.21 Application for exclusion of a non- Any controlled substance delivered narcotic substance. to the Administration under § 1307.21 or 1308.22 Excluded substances. forfeited pursuant to section 511 of the EXEMPT CHEMICAL PREPARATIONS Act (21 U.S.C. 881) may be delivered to any department, bureau, or other agen- 1308.23 Exemption of certain chemical prep- arations; application. cy of the United States or of any State 1308.24 Exemption chemical preparations. upon proper application addressed to the Administrator, Drug Enforcement EXCLUDED VETERINARY ANABOLIC STEROID Administration, Department of Jus- IMPLANT PRODUCTS tice, Washington, DC 28083. The appli- 1308.25 Exclusion of a veterinary anabolic cation shall show the name, address, steroid implant product; application. and official title of the person or agen- 1308.26 Excluded veterinary anabolic steroid cy to whom the controlled drugs are to implant products. be delivered, including the name and quantity of the substances desired and EXEMPTED PRESCRIPTION PRODUCTS the purpose for which intended. The de- 1308.31 Application for exemption of a non- livery of such controlled drugs shall be narcotic prescription product. ordered by the Administrator, if, in his 1308.32 Exempted prescription products. opinion, there exists a medical or sci- EXEMPT ANABOLIC STEROID PRODUCTS entific need therefor. 1308.33 Exemption of certain anabolic ster- SPECIAL EXEMPT PERSONS oid products; application. 1308.34 Exempt anabolic steroid products. § 1307.31 Native American Church. HEARINGS The listing of peyote as a controlled substance in Schedule I does not apply 1308.41 Hearings generally. 1308.42 Purpose of hearing. to the nondrug use of peyote in bona 1308.43 Waiver or modification of Rules. fide religious ceremonies of the Native 1308.44 Initiation of proceedings for rule- American Church, and members of the making. Native American Church so using pe- 1308.45 Request for hearing or appearance; yote are exempt from registration. Any waiver. person who manufactures peyote for or 1308.46 Burden of proof. distributes peyote to the Native Amer- 1308.47 Time and place of hearing. ican Church, however, is required to 1308.48 Final order. obtain registration annually and to 1308.49 Control required under international comply with all other requirements of treaty. law. 1308.50 Control of immediate precursors. 1308.51 Pending proceedings. 1308.52 Emergency sheduling. PART 1308ÐSCHEDULES OF AUTHORITY: 21 U.S.C. 811, 812, 871(b), unless CONTROLLED SUBSTANCES otherwise noted. Sec. SOURCE: 38 FR 8254, Mar. 30, 1973, unless otherwise noted. Redesignated at 38 FR 26609, GENERAL INFORMATION Sept. 24, 1973. 1308.01 Scope of Part 1308. GENERAL INFORMATION 1308.02 Definitions. 1308.03 Administration Controlled Sub- § 1308.01 Scope of Part 1308. stances Code Number. 1308.04 Submission of information by manu- Schedules of controlled substances facturers. established by section 202 of the Act (21 82 VerDate 14<JUN>96 10:36 Jul 12, 1996 Jkt 167073 PO 00000 Frm 00079 Fmt 8010 Sfmt 8010 C:\CFR\21V9C2.TXT pfrm13 Food and Drug Administration, HHS § 1308.02 U.S.C. 812), as they are changed, up- Services for such administration. If dated, and republished from time to any person prescribes, dispenses, or dis- time, are set forth in this part. tributes such steroid for human use, such person shall be considered to have § 1308.02 Definitions. prescribed, dispensed, or distributed an As used in this part, the following anabolic steroid within the meaning of terms shall have the meanings speci- this paragraph. fied: (c) The term hearing means any hear- (a) The term Act means the Con- ing held pursuant to this part for the trolled Substance Act (84 Stat. 1242; 21 issuance, amendment, or repeal of any U.S.C. 801) and/or the Controlled Sub- rule issuable pursuant to section 201 of stances Import and Export Act (84 the Act. Stat. 1285; 21 U.S.C. 951). (b) The term anabolic steroid means (d) The term isomer means the optical any drug or hormonal substance, isomer, except as used in § 1308.11(d) chemically and pharmacologically re- and § 1308.12(b)(4). As used in § 1308.11(d), lated to testosterone (other than the term isomer means the optical, po- estrogens, progestins, and sitional, or geometric isomer. As used corticosteroids) that promotes muscle in § 1308.12(b)(4), the term isomer means growth, and includes: the optical or geometric isomer. (1) Boldenone; (e) The term interested person means (2) Chlorotestosterone (4- any person adversely affected or ag- chlortestosterone); grieved by any rule or propored rule is- (3) Clostebol; suable pursuant to section 201 of the (4) Dehydrochlormethyltestosterone; Act. (5) Dihydrotestosterone (4- (f) The term narcotic drug means any dihydrotestosterone); of the following whether produced di- (6) Drostanolone; rectly or indirectly by extraction from (7) Ethylestrenol; substances of vegetable origin or inde- (8) Fluoxymesterone; (9) Formebulone (formebolone); pendently by means of chemical syn- (10) Mesterolone; thesis or by a combination of extrac- (11) Methandienone; tion and chemical synthesis: (12) Methandranone; (1) Opium, opiates, derivatives of (13) Methandriol; opium and opiates, including their iso- (14) Methandrostenolone; mers, esters, ethers, salts, and salts of (15) Methenolone; isomers, esters, and ethers whenever (16) Methyltestosterone; the existence of such isomers, esters, (17) Mibolerone; ethers and salts is possible within the (18) Nandrolone; specific chemical designation. Such (19) Norethandrolone; term does not include the isoquinoline (20) Oxandrolone; alkaloids of opium. (21) Oxymesterone; (2) Poppy straw and concentrate of (22) Oxymetholone; (23) Stanolone; poppy straw. (24) Stanozolol; (3) Coca leaves, except coco leaves (25) Testolactone; and extracts of coca leaves from which (26) Testosterone; cocaine, ecgonine and derivatives of ec- (27) Trenbolone; and gonine or their salts have been re- (28) Any salt, ester, or isomer of a moved. drug or substance described or listed in (4) Cocaine, its salts, optical and geo- this paragraph, if that salt, ester, or metric isomers, and salts of isomers. isomer promotes muscle growth. Ex- (5) Ecgonine, its derivatives, their cept such term does not include an an- salts, isomers and salts of isomers. abolic steroid which is expressly in- (6) Any compotnd, mixture, or prepa- tended for administration through im- ration which contains any quantity of plants to cattle or other nonhuman any of the substances referred to in species and which has been approved by subparagraphs (1) through (5). the Secretary of Health and Human 83 VerDate 14<JUN>96 10:36 Jul 12, 1996 Jkt 167073 PO 00000 Frm 00080 Fmt 8010 Sfmt 8010 C:\CFR\21V9C2.TXT pfrm13 § 1308.03 21 CFR Ch. II (4±1±96 Edition) (g) The term proceeding means all ac- tration Controlled Substances Code tions taken for the issuance, amend- Number for any purpose. ment, or repeal of any rule issued pur- [38 FR 8254, Mar. 30, 1973. Redesignated at 38 suant to section 201 of the Act, com- FR 26609, Sept. 24, 1973 and amended at 51 FR mencing with the publication by the 15318, Apr. 23, 1986] Administrator of the proposed rule, amended rule, or repeal in the FEDERAL § 1308.04 Submission of information by REGISTER. manufacturers. (h) Any term not defined in this sec- (a) Each person who manufactures, tion shall have the definition set forth packages, repackages, labels, relabels, in section 102 and 1001 of the Act (21 or distributes under his own label any U.S.C. 802 and 951) and § 1301.02 of this product (including any compound, mix- chapter. ture, or preparation, diagnostic, rea- [38 FR 8254, Mar. 30, 1973. Redesignated at 38 gent, buffer, or biological) containing FR 26609, Sept. 24, 1973, and amended at 51 any quantity of any controlled sub- FR 15317, Apr. 23, 1986; 56 FR 5754, Feb. 13, stance (whether such product is itself 1991] controlled or is excepted, exempted, or excluded from some or all controls pur- § 1308.03 Administration Controlled suant to § 1308.21±24 or § 1308.31±32) shall Substances Code Number. submit information required in para- (a) Each controlled substance, or graph (b) of this section for each such basic class thereof, has been assigned product being manufactured or sold on an ``Administration Controlled Sub- July 1, 1972. The information should be stances Code Number'' for purposes of submitted by registered mail, return identification of the substances or receipt requested, to the Regulatory class on certain Certificates of Reg- Support Section, Attention: Project istration issued by the Administration Label, Drug Enforcement Administra- pursuant to §§ 1301.44 and 1311.43 of this tion, Department of Justice, Washing- chapter and on certain order forms is- ton, DC 20537, by August 31, 1972. In the sued by the Administration pursuant case of new products manufactured to § 1305.05(d) of this chapter. Appli- after July 1, 1972, or new dosage forms cants for procurement and/or individ- or other unit forms manufactured after ual manufacturing quotas must include July 1, 1972, or changes in information the appropriate code number on the ap- submitted by August 31, 1972, the reg- plication as required in §§ 1303.12(b) and istrant shall submit the information 1303.22(a) of this chapter. Applicants regarding such item within 30 days for import and export permits must in- after the date on which the manufac- clude the appropriate code number on ture commences or information change occurs.
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Telazol® CIII(Tiletamine and Zolazepam for Injection)
    TELAZOL- tiletamine hydrochloride and zolazepam hydrochloride injection, powder, for solution Zoetis Inc. ---------- Telazol® CIII (tiletamine and zolazepam for injection) 100 mg/mL total (equivalent to 50 mg/mL tiletamine and 50 mg/mL zolazepam) For Intramuscular and Intravenous injection in Dogs For Intramuscular injection only in Cats CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION TELAZOL (tiletamine and zolazepam for injection) is a nonnarcotic, nonbarbiturate, injectable anesthetic agent for dogs and cats. Chemically, TELAZOL is a combination of equal parts by weight of base of tiletamine hydrochloride (2-[ethylamino]-2-[2-thienyl]-cyclohexanone hydrochloride), an arylaminocycloalkanone dissociative anesthetic, and zolazepam hydrochloride (4-[o-fluorophenyl]-6, 8-dihydro-1,3,8- trimethylpyrazolo [3, 4-e][1,4] diazepin-7 [1H]-1- hydrochloride), a nonphenothiazine diazepinone having minor tranquilizing properties. The product is supplied sterile in vials. The addition of 5 mL diluent produces a solution containing the equivalent of 50 mg tiletamine base, 50 mg zolazepam base and 57.7 mg mannitol per milliliter. This solution has a pH of 2 to 3.5 and is recommended for deep intramuscular injection. INDICATIONS Dogs TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia. (See Dogs under Dosage and Administration.) TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. Cats TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.
    [Show full text]
  • Oral Fluid Drug Test Package Insert
    Marijuana (THC) 11-nor-Δ9-THC-9 COOH 4 MTD: Methadone is a synthetic analgesic drug originally used for the Oral Fluid Drug Test treatment of narcotic addiction. In addition to use as a narcotic agonist, methadone is being used more frequently as a pain management agent. The Marijuana (THC) Δ9-THC 50 Package Insert psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Based on the saliva/plasma ratio calculated over Package insert for testing of the following drugs: > 0.02 % Alcohol (ALC) Alcohol salivary pH ranges of 6.4-7.6 for therapeutic or recreational doses of Amphetamine,Cocaine,Marijuana,Methamphetamine,Opiate,Methadone, B.A.C methadone, a cut-off <50 ng/mL is suggested. Due to this recommendation, Phencyclidine,Oxycodone,Benzodiazepine,Buprenorphine,Barbiturates, the cut-off level of the methadone test was calibrated to 30 ng/mL. Cotinine,EDDP,MDMA,6-MAM,Propoxyphene ,Fentanyl,ETG and Alcohol Tramadol(TRA) 50 Tramadol PCP: Phencyclidine is a hallucinogen and, can be detected in oral fluid as a INTENDED USE & SUMMARY result of the exchange of the drug between the circulatory system and the oral cavity.5 Fentanyl(FEN) 10 The Oral Fluid Drug And Alcohol Test is intended for screening for the Norfentanyl presence of drugs and alcohol and their metabolites in oral fluid. For professional in vitro diagnostic use only. OXY: Oxycodone is a semi-synthetic opioid with a structural similarity to Ethyl codeine. The drug is manufactured by modifying thebaine, an alkaloid found in 150 The Oral Fluid Pipette Test is a lateral flow chromatographic immunoassay for Glucuronide(ETG) the opium poppy.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062165 B. Purpose for Submission: New device C. Measurand: Barbiturates D. Type of Test: Qualitative and semi-quantitative enzyme immunoassay E. Applicant: Ortho-Clinical Diagnostics, Inc. F. Proprietary and Established Names: VITROS Chemistry Products BARB Reagent VITROS Chemistry Products Calibrator 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, III, IV and V G. Regulatory Information: 1. Regulation section: 21 CFR 862.3150, Barbiturates test system 21 CFR 862.3200, Clinical Toxicology Calibrator 21 CFR 862.3180, Clinical Toxicology Control 2. Classification: Class II, (reagent, calibrator) Class I, reserved (control) 3. Product code: DIS, DLJ and DIF 4. Panel: Toxicology (91) 1 H. Intended Use: 1. Intended use(s): See Indications for use. 2. Indication(s) for use: VITROS Chemistry Products BARB Reagent: For in vitro diagnostic use only. VITROS Chemistry Products BARB Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi- quantitative or qualitative determination of barbiturates (BARB) in human urine using a cutoff of 200 ng/mL or 300 ng/mL. Measurements obtained with the VITROS BARB method are used in the diagnosis and treatment of barbiturates use or overdose. The VITROS Chemistry Products BARB assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result with this assay. Gas Chromatograpy/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Brain Choline Acetyltransferase Activity in Chronic, Human Users of Cocaine
    Molecular Psychiatry (1999) 4, 26–32 1999 Stockton Press All rights reserved 1359–4184/99 $12.00 ORIGINAL RESEARCH ARTICLE Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin SJ Kish1, KS Kalasinsky2, Y Furukawa1, M Guttman1, L Ang3,LLi4, V Adams5, G Reiber6, RA Anthony6, W Anderson7, J Smialek4 and L DiStefano1 1Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Canada; 2Division of Forensic Toxicology, Armed Forces Institute of Pathology, Washington, DC, USA; 3Department of Pathology (Neuropathology), Sunnybrook Hospital, Toronto, Canada; 4Department of Pathology, University of Maryland, Baltimore, MD; 5Office of the Hillsborough County Medical Examiner, Tampa, FL; 6Northern California Forensic Pathology, Sacramento, CA; 7Office of the Medical Examiner of District 9, Orlando, FL, USA Cognitive impairment has been reported in some chronic users of psychostimulants, raising the possibility that long-term drug exposure might damage brain neuronal systems, including the cholinergic system, which are responsible for normal cognition. We measured the activity of choline acetyltransferase (ChAT), the marker enzyme for cholinergic neurones, in autopsied brain of chronic users of cocaine, methamphetamine, and, for comparison, heroin. As com- pared with the controls, mean ChAT levels were normal in all cortical and subcortical brain areas examined. However, the two of 12 methamphetamine users, who had the highest brain/blood drug levels at autopsy, had a severe (up to 94%) depletion of ChAT activity in cerebral cortex, striatum, and thalamus. Based on the subjects examined in the present study, our neurochemical data suggest that brain cholinergic neurone damage is unlikely to be a typical feature of chronic use of cocaine, methamphetamine, or heroin, but that exposure to very high doses of methamphetamine could impair, at least acutely, cognitive function requir- ing a normal nucleus basalis cholinergic neuronal system.
    [Show full text]